IVA337



NAME OF DRUG : LANIFIBRANOR

ALSO KNOWN AS : IVA337

LABORATORY : INVENTIVA

STATUS AND ADVANCEMENT

Type of drug : tri PPAR α δ γ

Clinical trials advancement : Initiating Phase 2b

Estimated time to market : 106 months.

LABORATORY ABSTRACT ON THE DRUG

LANIFIBRANOR - IVA337, which has demonstrated anti-fibrotic properties in several tissues alongside good clinical tolerance, is currently in a Phase IIb trial for the treatment of systemic sclerosis, another fibrotic disease with very high unmet medical needs. IVA337 has undergone a successful Phase IIa study in diabetic patients with improvements in markers of insulin resistance (HOMA-IR), and dyslipidemia (increase in circulating HDL cholesterol and decrease of circulating triglycerides). These clinical findings are extremely valuable as the physiopathology of NASH is intimately linked to obesity, IR and T2DM. Furthermore data generated in multiple relevant pre-clinical models demonstrated that IVA337 also positively impacts all hepatic lesions associated with NASH. In these pre-clinical studies, IVA337 significantly reduced steatosis, ballooning and inflammation, and reversed established liver fibrosis.

RECENT NEWS ON IVA337

2017-09-18 : Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)

2017-06-20 : Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models

2017-02-02 : Inventiva launches its initial public offering on the regulated market of Euronext Paris

2017-01-03 : Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

SOME PUBLICATIONS RELATED WITH IVA337

January 2015 : The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH IVA337


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE